All In Biotech

Drug Trial Radar · NCT03129646

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Last checked: Nov 20, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 439 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

439

Actual

Start

Jan 24, 2018

Primary completion

Dec 11, 2020

Study completion Dec 11, 2020

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Netherlands Cancer Institute; The Institute of Endemic Diseases (IEND), University of Khartoum; Kenya Medical Research Institute; Makerere University; University of Gondar
First posted
Apr 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.

Conditions

  • Visceral Leishmaniasis

Interventions

  • MiltefosineDrug

    Miltefosine 10mg and 50mg capsules

  • ParomomycinDrug

    Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp

  • Sodium stibogluconateDrug

    Sodium stibogluconate 33% 30 ml inj.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Definitive CureTime frame: 6 months follow-up (Day 210)

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • University Hospital of Gondar

    Gonder, Ethiopia

  • Abdurafi MSF Health Center

    Ābderafī, Amhara, Ethiopia

  • Kacheliba Hospital

    Kapenguria, West Pokot County, Kenya

  • Um El Kher Hospital

    Gedaref, Sudan

  • El Hassan Centre for Tropical Medicine

    Doka, Al Qaḑārif, Sudan

  • Tabarak Allah MSF Hospital

    Gedaref, Al Qaḑārif, Sudan

  • Amudat Hospital

    Amudat, Karamoja, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.